Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc Fundamental Analysis
Centessa Pharmaceuticals plc (CNTA) shows weak financial fundamentals with a PE ratio of -13.53, profit margin of -16.18%, and ROE of -67.68%. The company generates $0.0B in annual revenue with weak year-over-year growth of -1.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -1357.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CNTA's fundamental strength across five key dimensions:
Efficiency Score
WeakCNTA struggles to generate sufficient returns from assets.
Valuation Score
ModerateCNTA shows balanced valuation metrics.
Growth Score
WeakCNTA faces weak or negative growth trends.
Financial Health Score
ExcellentCNTA maintains a strong and stable balance sheet.
Profitability Score
WeakCNTA struggles to sustain strong margins.
Key Financial Metrics
Is CNTA Expensive or Cheap?
P/E Ratio
CNTA trades at -13.53 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CNTA's PEG of 6.05 indicates potential overvaluation.
Price to Book
The market values Centessa Pharmaceuticals plc at 10.89 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -14.18 times EBITDA. This is generally considered low.
How Well Does CNTA Make Money?
Net Profit Margin
For every $100 in sales, Centessa Pharmaceuticals plc keeps $-16.18 as profit after all expenses.
Operating Margin
Core operations generate -14.25 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-67.68 in profit for every $100 of shareholder equity.
ROA
Centessa Pharmaceuticals plc generates $-54.14 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Centessa Pharmaceuticals plc generates limited operating cash flow of $-181.16M, signaling weaker underlying cash strength.
Free Cash Flow
Centessa Pharmaceuticals plc generates weak or negative free cash flow of $-181.52M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.35 in free cash annually.
FCF Yield
CNTA converts -5.50% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-13.53
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
6.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
10.89
vs 25 benchmark
P/S Ratio
Price to sales ratio
219.29
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.39
vs 25 benchmark
Current Ratio
Current assets to current liabilities
10.57
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.68
vs 25 benchmark
ROA
Return on assets percentage
-0.54
vs 25 benchmark
ROCE
Return on capital employed
-0.51
vs 25 benchmark
How CNTA Stacks Against Its Sector Peers
| Metric | CNTA Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -13.53 | 29.43 | Better (Cheaper) |
| ROE | -67.68% | 800.00% | Weak |
| Net Margin | -1617.99% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.39 | 0.30 | Weak (High Leverage) |
| Current Ratio | 10.57 | 4.64 | Strong Liquidity |
| ROA | -54.14% | -17936.00% (disorted) | Weak |
CNTA outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Centessa Pharmaceuticals plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-4049.96%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-2168.31%
Industry Style: Defensive, Growth, Innovation
Declining